Message from the Helsinn Group's CEO
Helsinn builds a franchise in supportive care to become a “Quality of Life Company”
4Ps make 1QoL company!
Our Passion, our People, our Products, and our Patience are certainly shaping the Helsinn
Group into the premier Quality of Life company.
Passion is our determination to work hard every day, enjoy our jobs, work in goal-oriented teams, to develop products from early phases of development through the launch onto the
People make Helsinn grow: we hire well trained, qualified executives and employees who share our vision and work with passion.
Products are what passion and people build year by year. We are concentrated on developing innovative products to improve the patients’ quality of life and offer solutions to physicians and caregivers. Cancer supportive care is our main focus, but we are also active in the areas of pain and inflammation, gastroenterology and metabolism.
Patience has been characteristic of the Helsinn Group since its foundation more than 35 years ago. Our family business is growing in a cautious yet flexible and market-oriented manner.
The 4Ps are the engine that will enable us to fulfill our commitment to becoming the premier Quality of Life company. Our unique business model and distinctive profile are perfectly reflected by our corporate slogan “Shaping alliances, building pharmaceuticals”.
We have shaped alliances with Eisai U.S., Taiho, in Japan, and with many other pharmaceutical companies in Europe, Latin America, Asia-Pacific region and Africa not only to optimize the commercial success of our leading product, Aloxi®, for the treatment of nausea and emesis induced by anticancer treatments, but also the commercial success of our other medicines and medical devices.
Helsinn’s expertise in developing products and in building pharmaceuticals is reflected in our pipeline. In 2011, two new very promising products entered phase III of clinical development:
netupitant-palonosetron fixed dose combination, for the prevention of chemotherapy induced nausea and vomiting, and anamorelin for the treatment of non-small cell lung cancer associated anorexia-cachexia. In addition, Helsinn is investing in a new generation of compounds acting on the ghrelin receptor, and in food supplements.
The implementation of our strategy, planned only 5 years ago in 2007, is already yielding plenty of fruit, as expected.
Dr. Riccardo Braglia
Group Chief Executive Officer
Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals, with the recent additions of medical devices in therapeutic niche areas.
Helsinn is an important player in Cancer Supportive Care
Helsinn in-licenses early-to-late stage new chemical entities from small and big pharma companies, completes their development through the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development and files and attains their market approval worldwide. The Group markets its products directly through its network of local pharmaceutical partners, selected for their deep in-market knowledge and know-how, whom Helsinn assists and supports with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage products are manufactured to the highest quality, safety and environmental standards, in compliance with U.S. FDA, EU EMA, Swissmedic, Japanese PMDA and PIC requirements at Helsinn’s facilities in Switzerland and Ireland, and supplied worldwide to its customers.
Helsinn's business approach
Board of Directors and Top Management